|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide based on the C terminal end of the catalytic domain of human CD26 / DPP4|
|Purification||Antigen affinity chromatography|
|Storage buffer||50% glycerol|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:1000 - 1:5000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA1-8455 detects DPP-4 from human, mouse, and rat samples. This antibody does not cross-react with other DPP family members.
PA1-8455 has been successfully used in Western blotting procedures. By Western blot, this antibody detects ~120 kDa proteins representing DPP-4.
EDTA/EGTA treatment of tissues or lysates is required to see latent zymogen.
PA1-8455 immunizing peptide is based on the stalk region of human DPP-4.
CD26, also known as dipeptidyl peptidase IV (DPP-IV), is a homodimeric cell surface serine peptidase that degradates IFN-gamma-induced cytokines, acts as a T cell costimulatory molecule, and participates in multiple immunopathological roles in leukocyte homing and inflammation. Alterations in its peptidase activity are characteristic of malignant transformation. The enzymatic activity increases dramatically with tumour grade and severity. CD26 is expressed in various blood cell types, but also e.g. in cells that are histogenetically related to activated fibroblasts. Alterations in CD26 density have been reported on circulating monocytes and CD4+ T cells during rheumatoid arthritis and systemic lupus erythematosus.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.